help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vignon, F.
Right arrow Articles by Rochefort, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vignon, F.
Right arrow Articles by Rochefort, H.

Journal of Clinical Endocrinology & Metabolism, Vol 56, 1124-1130, Copyright © 1983 by Endocrine Society

ARTICLES

Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture

F Vignon, S Bardon, D Chalbos and H Rochefort

To see whether progestins prevent estrogen action in breast cancer cells, we have studied in vitro the effect of R5020 on the cell growth and the synthesis of secreted proteins in T47D and R27 human breast cancer cells. While R5020 had no effect on cell growth when tested alone, it significantly inhibited the growth of both cell lines in the presence of estradiol (1 nM). The effect was most clear-cut after 10-12 days of treatment and was dose dependent, a half-maximal inhibition occurred with 1 nM R5020. R27, a cloned MCF7 variant resistant to Tamoxifen, remained responsive to R5020, which prevented the effect of 17 beta-estradiol (E2) and inhibited cell growth in the presence of Tamoxifen. This suggests that the two antiestrogens are acting through different mechanisms. Dihydrotestosterone and dexamethasone did not reproduce or inhibit the effect of R5020 on cell growth. R5020 was ineffective in a rat tumor cell line containing androgen and glucocorticoid receptors but lacking progesterone receptors and estrogen receptors. These results suggest that R5020 is probably acting via progesterone receptors rather than via the androgen or glucocorticoid receptors. Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, we have shown that R5020 specifically decreases the production of the 52K protein, a major protein released by R27 cells after E2 stimulation. We conclude that R5020 has an antiestrogenic activity on breast cancer cells in culture, since it prevents the stimulation of cell growth and protein synthesis by E2.


This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
T.A. Richter, J.E. Robinson, and N.P. Evans
Progesterone Blocks the Estradiol-Stimulated Luteinizing Hormone Surge by Disrupting Activation in Response to a Stimulatory Estradiol Signal in the Ewe
Biol Reprod, July 1, 2002; 67(1): 119 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Swarbrick, C. S. L. Lee, R. L. Sutherland, and E. A. Musgrove
Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells
Mol. Cell. Biol., April 1, 2000; 20(7): 2581 - 2591.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
E. A. Musgrove, A. Swarbrick, C. S. L. Lee, A. L. Cornish, and R. L. Sutherland
Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins
Mol. Cell. Biol., April 1, 1998; 18(4): 1812 - 1825.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society